Skip to main navigation Press Releases Year 2021 November 23, 2021 Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference November 8, 2021 Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors October 26, 2021 Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates October 19, 2021 Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress October 12, 2021 Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021 September 9, 2021 Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis September 1, 2021 Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference August 12, 2021 Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer July 28, 2021 Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates July 20, 2021 Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 10 of 32 TOOLKIT Print Page RSS Feeds Email Alerts Contact Search © 2021 Myovant Sciences GmbH. All rights reserved. Terms of Use Privacy Policy Cookie Policy Compliance & Prescriber Information